CHMP adopts positive opinion of Keytruda + Padcev for unresectable or metastatic urothelial carcinoma

Phase III trial of subcutaneous pembrolizumab with berahyaluronidase alfa meets primary endpoints

Merck announced positive topline results from the pivotal phase III MK-3475A-D77 trial.

November 22, 2024

Data from Gardasil 9 studies reinforce importance of gender-neutral HPV vaccination in adults

Clinical and real-world data for the 9-valent human papillomavirus vaccine, Gardasil 9, evaluating the burden and incidence of certain HPV-related cancers and diseases, were presented at the International Papillomavirus Conference 2024 in Edinburgh, UK, from Nov. 12-15.

November 15, 2024

Vol.50 No.43

Clinical Roundup

Keytruda improves outcomes in soft tissue sarcoma

Addition of the immunotherapy drug pembrolizumab (Keytruda) to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results of the SU2C-SARC032 clinical trial led by researchers from the University of Pittsburgh, UPMC, Duke University, and Princess Margaret Cancer Centre.

November 15, 2024

Vol.50 No.43

Clinical Roundup

Phase I clinical trial of Keytruda + Lymphir for recurrent solid tumors yields positive preliminary results

Promising preliminary results from an ongoing investigator-initiated phase I clinical trial evaluating the safety and efficacy of a combined regimen of Keytrua (pembrolizumab) and Lymphir (denileukin diftitox-cxdl or E7777) in patients with recurrent solid tumors were announced.

November 15, 2024

Vol.50 No.43

In Brief

Merck acquires Modifi Biosciences

Modifi Biosciences Inc., a Yale University spinout company formed in 2021 that develops direct DNA-modification-enabled cancer therapeutics, has been acquired by Merck.

October 25, 2024

Vol.50 No.40

Drugs & Targets

EC approves Keytruda combinations for endometrial carcinoma indication, FIGO 2014 stage III-IVA locally advanced cervical cancer

The European Commission has approved two new indications for Keytruda (pembrolizumab), an anti-PD-1 therapy, in gynecologic cancers.

October 25, 2024

Vol.50 No.40

CHMP adopts positive opinion of Keytruda + Padcev for unresectable or metastatic urothelial carcinoma

YOU MAY BE INTERESTED IN

Phase III trial of subcutaneous pembrolizumab with berahyaluronidase alfa meets primary endpoints

Data from Gardasil 9 studies reinforce importance of gender-neutral HPV vaccination in adults

Keytruda improves outcomes in soft tissue sarcoma

Phase I clinical trial of Keytruda + Lymphir for recurrent solid tumors yields positive preliminary results

Merck acquires Modifi Biosciences

EC approves Keytruda combinations for endometrial carcinoma indication, FIGO 2014 stage III-IVA locally advanced cervical cancer

Renew today!

Subscriber content

Never miss an issue!

Login